MedTrace Logo

the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)

NCT03264794 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-08-29

No results posted yet for this study

Summary

1. Gefitinib CTTQ production gefitinib and erlotinib sheet AstraZeneca imatinib sheet (trade name: Iressa ®) comparison, human pharmacokinetics and relative bioavailability of comparative studies which examine people in vivo pharmacokinetic behavior, provide the basis for clinical use.
2. Evaluation CTTQ gefitinib imatinib sheet production efficacy and safety of Chinese patients with locally advanced or metastatic non-small cell lung cancer.

Conditions

Interventions

DRUG

Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial

Gefitinib Tab （CTTQ），First medication,250mg；

DRUG

Gefitinib tablets (Yi Ruisha），First medication

Gefitinib tablets (Yi Ruisha），First medication,250mg；

DRUG

Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.

From the 8th day of the experiment, two groups of subjects were treated with Gefitinib（CTTQ）

Sponsors & Collaborators

  • Jiangsu Famous Medical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-31
Primary Completion
2021-12-31
Completion
2022-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03264794 on ClinicalTrials.gov